Related Experiment Video
Updated: Mar 2, 2026
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
Published on: April 11, 2018
Evolving Treatment of Soft Tissue Sarcoma
1Presented by Suzanne George, MD, Center for Sarcoma and Bone Oncology, Dana-Farber/Brigham and Women's Cancer Center, and Harvard Medical School, Boston, Massachusetts.
Abstract:
Soft tissue sarcomas comprise multiple histologic subtypes, occur at a number of anatomic sites, and require individualized treatment. Over the past 5 years, 4 new drugs were approved for sarcoma, most of which are driven by histology or the anticipated response to treatment. Surgical resection remains the primary treatment for resectable tumors. For unresectable or metastatic disease, doxorubicin remains the backbone of chemotherapy, but other agents have improved on its single-agent efficacy. Chief among them is olaratumab, which, in combination with doxorubicin, is preferred over doxorubicin alone in the updated NCCN Clinical Practice Guidelines in Oncology for Soft Tissue Sarcoma.
Insights
New chemotherapy options offer improved efficacy for unresectable or metastatic soft tissue sarcomas. Olaratumab combined with doxorubicin is now preferred over doxorubicin alone, according to updated guidelines.
Area of Science:
- Oncology
- Medical Oncology
- Cancer Research
Background:
- Soft tissue sarcomas are a diverse group of cancers requiring tailored treatment strategies.
- Recent advancements have led to the approval of four new drugs for sarcoma treatment over the last five years.
- Histology and predicted treatment response are key factors in selecting appropriate therapies.
Purpose of the Study:
- To review the current treatment landscape for soft tissue sarcomas.
- To highlight advancements in chemotherapy for unresectable or metastatic disease.
- To emphasize the updated NCCN guidelines regarding olaratumab and doxorubicin combination therapy.
Main Methods:
- Review of recent clinical trials and drug approvals in sarcoma treatment.
- Analysis of chemotherapy efficacy for unresectable and metastatic soft tissue sarcomas.
- Incorporation of updated National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines.
Main Results:
- Surgical resection is the standard for resectable soft tissue sarcomas.
- Doxorubicin is the established chemotherapy backbone for unresectable or metastatic disease.
- Olaratumab in combination with doxorubicin demonstrates improved efficacy compared to doxorubicin monotherapy.
Conclusions:
- Treatment for soft tissue sarcomas must be individualized based on histologic subtype and disease status.
- The combination of olaratumab and doxorubicin represents a preferred chemotherapy option for advanced soft tissue sarcomas.
- Updated clinical guidelines reflect the enhanced efficacy of novel therapeutic combinations in sarcoma management.
Related Concept Videos
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...